News Story Headlines
September 25, 2024
2024 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter here!
August 30, 2024
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 30, 2024– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in...
June 25, 2024
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Jun 24, 2024
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 24, 2024– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase...
April 23, 2024
January 18, 2024